BR1010 in Patients With Essential Hypertension Patients Who do Not Adequately Respond to Fimasartan/Amlodipine Combination
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 257 participants.
Also called NCT03991442
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 257 participants
- Registry
-
NCT03991442
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT03991442. Randomized; triple masking; primary purpose treatment. Start 2019-06-17 (actual); primary completion 2021-03-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- BR1010 in Patients With Essential Hypertension Patients Who do Not Adequately Respond to Fimasartan/Amlodipine Combination
- Acronym
- FINAL
- Condition
- Essential Hypertension
- Intervention (Drug)
- Fimasartan/Amlodipine
- Lead sponsor
- Boryung Pharmaceutical Co., Ltd
Record details
- Record id
cardio:ct-nct03991442- Content hash
0bea2090caa37c5e0c7c0f9c638509eb727c8f467bd8c77ea84e6b99f88c7a0c